Effective laboratory markers for the estimation of disease severity and predicting the clinical progression of coronavirus disease‐2019 (COVID‐19) is urgently needed. Laboratory tests, including blood routine, cytokine profiles and infection markers, were collected from 389 confirmed COVID‐19 patients. The included patients were classified into mild (n  = 168), severe (n  = 169) and critical groups (n  = 52). The leukocytes, neutrophils, infection biomarkers [such as C‐reactive protein (CRP), procalcitonin (PCT) and ferritin] and the concentrations of cytokines [interleukin (IL)‐2R, IL‐6, IL‐8, IL‐10 and tumor necrosis factor (TNF)‐α] were significantly increased, while lymphocytes were significantly decreased with increased severity of illness. The amount of IL‐2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL‐2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL‐2R/lymphocytes were superior compared with other markers for the identification of COVID‐19 with critical illness, not only from mild but also from severe illness. Moreover, the cytokine profiles and IL‐2R/lymphocytes were significantly decreased in recovered patients, but further increased in disease‐deteriorated patients, which might be correlated with the outcome of COVID‐19. Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL‐2R/lymphocyte was a prominent biomarker for early identification of severe COVID‐19 and predicting the clinical progression of the disease.

中文翻译：

---

使用IL-2R /淋巴细胞预测COVID-19患者的临床进展。

迫切需要有效的实验室标记物来估计疾病的严重程度并预测冠状病毒病2019（COVID-19）的临床进展。从389名确诊的COVID-19患者中收集了包括血液常规，细胞因子谱和感染标志物在内的实验室检查。纳入的患者分为轻度（n  = 168），重度（n  = 169）和严重（n = 52）。白细胞，中性粒细胞，感染生物标志物[例如C反应蛋白（CRP），降钙素原（PCT）和铁蛋白]以及细胞因子的浓度[白介素（IL）-2R，IL-6，IL-8，IL-10和随着疾病严重程度的增加，肿瘤坏死因子（TNF）-α]显着增加，而淋巴细胞显着减少。IL-2R的含量与其他细胞因子呈正相关，与淋巴细胞数量呈负相关。发现重症和重症患者中IL-2R与淋巴细胞的比率显着增加。与其他标志物相比，IL-2R /淋巴细胞优于其他标志物，不仅可以鉴定轻度疾病，还可以鉴定严重疾病。此外，康复患者的细胞因子概况和IL-2R /淋巴细胞明显减少，但疾病恶化的患者进一步增加，这可能与COVID-19的结果有关。淋巴细胞减少和细胞因子水平升高与疾病严重程度密切相关。IL-2R /淋巴细胞是早期识别严重COVID-19并预测疾病临床进展的重要生物标志物。